Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2023-01-09 00:00:00 ET · period of report 2023-01-05 · accession 0001714899-23-000015 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-09 | 2023-01-05 | DNLI | Krognes Steve E. | Dir | S - Sale | $28.44 | -2,970 | 146.5K | -2% | -$84.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-05 | S | D | 2,970 | $28.44 | 146,498 | D | — | — | (F2) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.17 to $28.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Includes 43,822 restricted stock units. |